Precision BioSciences AI Stock Analysis
Want to see DTIL full AI Analyst Report?
Precision BioSciences (DTIL) AI Stock Analysis
Precision BioSciences
(NASDAQ:DTIL)
The score is held back primarily by weak financial performance—large ongoing losses and substantial negative operating/free cash flow—despite a relatively low-debt balance sheet. Technicals add support due to strong upside momentum, but overbought indicators temper that strength. Corporate events are a net positive given fresh financing and encouraging clinical updates, while valuation is difficult to support with a negative P/E and no dividend yield provided.
Precision BioSciences (DTIL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $198.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 321.46K
- Price to Earnings (P/E)
- -5.8
- Beta (1Y)
- 0.07
- Revenue Growth
- 6353.01%
- EPS Growth
- 84.80%
- Country
- US
- Employees
- 69
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Precision BioSciences Business Overview & Revenue Model
Company Description
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome...
How the Company Makes Money
Precision BioSciences primarily generates revenue through collaboration-related arrangements rather than product sales (to the extent commercial products are not available or not material). Key revenue streams typically include: (1) upfront payments...
Precision BioSciences Financial Statement Overview
Summary
Overall fundamentals are weak due to persistently negative profitability and heavy cash burn. The income statement shows volatile revenue and deeply negative TTM net margin (~-86%), while cash flow is a major risk with TTM operating/free cash flow around -$51.8M. The balance sheet is comparatively healthier (very low debt of ~$1.7M vs. ~$51.8M equity), but ROE is materially negative (~-58%), reflecting ongoing losses.
Income Statement
28NegativeBalance Sheet
62PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.04M | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| Gross Profit | 44.46M | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| EBITDA | -48.81M | -42.43M | 13.53M | -32.04M | -62.79M | -20.27M |
| Net Income | -38.55M | -45.72M | 7.17M | -61.32M | -111.64M | -30.60M |
Balance Sheet | ||||||
| Total Assets | 120.38M | 154.42M | 136.39M | 159.78M | 238.17M | 211.50M |
| Cash, Cash Equivalents and Short-Term Investments | 81.85M | 115.58M | 86.31M | 116.68M | 189.58M | 143.66M |
| Total Debt | 27.72M | 28.81M | 30.05M | 31.27M | 24.96M | 9.11M |
| Total Liabilities | 68.60M | 62.17M | 80.00M | 140.92M | 177.74M | 120.33M |
| Stockholders Equity | 51.77M | 92.25M | 56.39M | 18.86M | 60.43M | 91.17M |
Cash Flow | ||||||
| Free Cash Flow | -51.81M | -65.93M | -58.70M | -86.39M | -49.07M | -16.66M |
| Operating Cash Flow | -51.76M | -65.84M | -58.45M | -84.11M | -45.75M | -10.85M |
| Investing Cash Flow | -638.00K | -634.00K | -215.00K | 5.83M | -3.32M | -5.80M |
| Financing Cash Flow | 89.22M | 95.16M | 50.45M | 5.39M | 94.98M | 70.52M |
Precision BioSciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Negative. The current price of 7.10 is below the 20-day moving average (MA) of 7.82, above the 50-day MA of 7.00, and above the 200-day MA of 6.81, indicating a neutral trend. The MACD of 0.22 indicates Positive momentum. The RSI at 45.19 is Neutral, neither overbought nor oversold. The STOCH value of 4.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DTIL.
Precision BioSciences Risk Analysis
Precision BioSciences disclosed 75 risk factors in its most recent earnings report. Precision BioSciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskPrecision BioSciences Peers Comparison
Overall Rating
DTIL54Neutral
ACET49Neutral
CTMX46Neutral
IMA44Neutral
ACRV42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 54Neutral | $198.34M | -5.77 | -58.09% | ― | 6353.01% | 84.80% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $26.03M | -0.29 | -69.71% | ― | ― | 57.60% | |
| 46Neutral | $409.85M | -4.17 | -33.97% | ― | -87.66% | -210.45% | |
| 44Neutral | $48.58M | -1.23 | -32.90% | ― | ― | 61.67% | |
| 42Neutral | $66.94M | -0.85 | -80.87% | ― | ― | 14.08% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DTIL | Precision Biosciences | 7.10 | 2.10 | 42.00% | |
| CTMX | CytomX Therapeutics Inc. | 1.88 | -2.00 | -51.55% | |
| ACET | Adicet Bio Inc | 2.50 | -7.14 | -74.06% | |
| IMA | Imagenebio, Inc. | 3.81 | -3.30 | -46.41% | |
| ACRV | Acrivon Therapeutics, Inc. | 1.56 | -0.74 | -32.17% |
Precision BioSciences Corporate Events
Precision BioSciences Expands Capital Resources Through Public Offering
PositiveOn November 5, 2026, Precision BioSciences entered into an underwriting agreement for an offering of 10,235,077 common shares at $7.75 each and pre-funded warrants to purchase up to 5,893,964 shares at $7.749995 per warrant. The financing expanded th...
Precision BioSciences Prices $125 Million Public Offering
PositiveOn November 5, 2026, Precision BioSciences entered an underwriting agreement and priced an offering of 10,235,077 common shares at $7.75 each and pre-funded warrants for up to 5,893,964 shares at $7.749995 each. The company expected approximately $12...
Precision BioSciences Reports Positive Clinical Trial Updates
PositiveOn November 5, 2026, Precision BioSciences reported new and updated preliminary Phase 1 ELIMINATE-B data for PBGENE-HBV, with 25 patients receiving 59 administrations across four dose levels by September 28, 2026. At the selected 0.4 mg/kg dose, all...
Precision BioSciences Begins First DMD Gene-Editing Trial
PositiveOn August 24, 2026, Precision BioSciences announced that it had dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD at Arkansas Children’s Hospital, marking the first clinical gene-editing program for Duchenne muscular...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
